Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: Design of a double-blind, randomised, placebo-controlled phase II trial

BMJ Open Respiratory Research

Volumn 5, Issue 1, 2018, Pages

  Maher, Toby M ^a,b   Corte, Tamera J ^c,d   Fischer, Aryeh ^e   Kreuter, Michael ^f   Lederer, David J ^g   Molina Molina, Maria ^h,i   Axmann, Judit ^j   Kirchgaessler, Klaus Uwe ^j   Cottin, Vincent ^k,l  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Department of Medicine   (United States)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k LOUIS PRADEL HOSPITAL   (France)

^l UNIVERSITÉ LYON 1   (France)

more..

Author keywords

antifibrotic; interstitial pneumonia with autoimmune features; pirfenidone; unclassifiable interstitial lung disease

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MYCOPHENOLATE MOFETIL; PIRFENIDONE; PLACEBO;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAN DIEGO SHORTNESS OF BREATH QUESTIONNAIRE; SCORING SYSTEM; SIX MINUTE WALK TEST; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT OUTCOME; VERY ELDERLY;

EID: 85053133675     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2018-000289     Document Type: Article

References (42)

1. Skolnik K, Ryerson CJ. Unclassifiable interstitial lung disease: A review. Respirology 2016;21:51-6.
2. Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med 2013;19:453-9.
3. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
4. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
5. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013;42:750-7.
6. Hyldgaard C, Hilberg O, Muller A, et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014;108:793-9.
7. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103:1122-9.
8. Troy L, Glaspole I, Goh N, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2014;43:1529-30.
9. Zhang D, Liu Y. Surgical lung biopsies in 418 patients with suspected interstitial lung disease in China. Intern Med 2010;49:1097-102.
10. Musellim B, Okumus G, Uzaslan E, et al. Epidemiology and distribution of interstitial lung diseases in Turkey. Clin Respir J 2014;8:55-62.
11. Hyldgaard C, Bendstrup E, Wells AU, et al. Unclassifiable interstitial lung diseases: Clinical characteristics and survival. Respirology 2017;22:494-500.
12. Cottin V, Wells A. Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category? Eur Respir J 2013;42:576-9.
13. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976-87.
14. Ahmad K, Barba T, Gamondes D, et al. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 2017;123:56-62.
15. Oldham JM, Adegunsoye A, Valenzi E, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016;47:1767-75.
16. Leung SC, Churg AM, Leipsic JA, et al. Unclassifiable interstitial lung disease: an unresolved diagnostic dilemma. Respirol Case Rep 2015;3:85-8.
17. Sasano H, Hagiwara E, Kitamura H, et al. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy. BMC Pulm Med 2016;16:168.
18. Chartrand S, Swigris JJ, Stanchev L, et al. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respir Med 2016;119:150-4.
19. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
20. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
21. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
22. Ryerson CJ, Corte TJ, Lee JS, et al. A standardized diagnostic ontology for fibrotic interstitial lung disease. An international working group perspective. Am J Respir Crit Care Med 2017;196:1249-54.
23. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67:407-11.
24. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016;194:265-75.
25. Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017;4:e000212.
26. Walsh SLF, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016;4:557-65.
27. Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;193:745-52.
28. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708-19.
29. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013;40:640-6.
30. Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 2016;43:1672-9.
31. Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2016;4:445-53.
32. Genentech. Product label: Full prescribing information -Esbriet®. 2017. Http://www.gene.com/download/pdf/esbriet-prescribing. Pdf (accessed 19 Jun 2018).
33. European Medicines Agency. Summary of Product Characteristics -Esbriet (pirfenidone). 2018. Http://www.ema. Europa. Eu/ema/index.jsp? Curl=pages/medicines/human/medicines/002154/human-med-001417. Jsp& mid=WC0b01ac058001d124 (accessed 19 Jun 2018).
34. Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritisassociated interstitial lung disease (RA-ILD). Respir Med 2013;107:1247-52.
35. Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;194:989-97.
36. Johannson KA, Vittinghoff E, Morisset J, et al. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J 2017;50:1602406.
37. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016;47:243-53.
38. Vuga LJ, Milosevic J, Pandit K, et al. Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis. PLoS One 2013;8:e83120.
39. Vuga LJ, Tedrow JR, Pandit KV, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;189:966-74.
40. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
41. Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007;56:1685-93.
42. White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2016;194:1242-51.